Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with ITcytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117-and 382-fold, respectively, against the cell line Daudi, and 81-and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14-and 11-fold, respectively) and NH 4 Cl (nine-and 10-fold, respectively). However, the combination of NH 4 Cl and chloroquine induced more than an additive effect (145-and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 × 10 2.06 log) . To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH 4 Cl and chloroquine can be used instead of NH 4 Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo.
Introduction
Hematological malignancies are difficult to cure by chemotherapy, radiotherapy and/or surgery. Bone marrow transplantation has improved the outcome of treatment in many patients but relapses occur frequently in high risk patients. IT therapy seems an excellent additional treatment in view of the potent and specific killing of malignant cells in vitro as well as in vivo. 1, 2 ITs are constructed by linking chemically or genetically a cell binding moiety to a toxin. The commonly used toxins belong to the ribosome-inactivating proteins 3, 4 and monoclonal antibodies (MoAbs) are usually used as targeting moiety.
CD22 MoAbs bind to the B-lymphocyte cell adhesion molecule (Bl-CAM) that is expressed on the surface of B cells from the pro-B cell stage to the mature B cell stage. 5 Upon binding, the Bl-CAM/IT complex is rapidly internalized, whereafter the antigen is re-expressed. 6, 7 This makes Bl-CAM an optimal target for ITs. Several investigators have shown that CD22 ITs have a strong anti-B cell potency in vitro as well as in vivo. 6, [8] [9] [10] [11] [12] [13] [14] These findings resulted in clinical phase I/II studies. [15] [16] [17] [18] Though achieving some complete responses, treatment of these patients did not result in complete cure. Combining IT with enhancing agents may improve efficacy. Usually, enhancers influence the intracellular processing of the IT. There are several groups of IT enhancers such as carboxylic ionophores, calcium channel antagonists, lysosomotropic amines, calmodulin antagonists and protease inhibitors. 19 Enhancement by a particular agent may depend on the toxin, 20 on the target cell and on the intracellular routing of the IT which is, in turn, influenced by the antigen and the MoAb 21 that is used. Since ITs are to be used in vitro as well as in vivo, we investigated enhancers of CD22-rec ricin A cytotoxicity suitable for both applications.
The lysosomotropic amines NH 4 Cl and chloroquine inhibit intracellular IT degradation by neutralizing the endosomal and lysosomal pH, which results in postponement of activation of lysosomal proteases. 22 NH 4 Cl also induces a strong increase of newly synthesized lysosomal proteases released from the cell in proportion to the amount delivered to the lysosomes. 23 NH 4 Cl is toxic to patients and can therefore only be used to potentiate IT activity ex vivo. 24 Chloroquine has been used successfully to treat rheumatoid arthritis and various parasitic infections such as malaria. Chloroquine has been administered in combination with an IT for treating a B-CLL patient. 25 A 300 mg intramuscular dose of chloroquine administered on day 2 and 3 resulted in a peak level of 1 m on day 3. No conclusions could be drawn from this study due to the differences in IT dosages between the patients treated with the combination of IT and chloroquine and IT alone. 25 The carboxylic ionophores, monensin and nigericin, have been studied extensively. [26] [27] [28] [29] [30] These agents also neutralize the lysosomal pH but at higher concentrations than required for IT potentiation. 31 This indicates that the mechanism of enhancement by carboxylic ionophores differs from that by lysosomotropic amines. 31, 32 Monensin induces distortion and swelling of endosomes and the Golgi and multivesicular bodies 22 which may counteract the release of IT from the cell.
The protease inhibitors bacitracin, aprotinin, leupeptin and soybean trypsin inhibitor may enhance IT activity by reducing lysosomal IT degradation. The calcium channel blocker verapamil has been shown to enhance pseudomonas exotoxin, as well as ricin A IT activity. 33 However, this drug can only be used in vitro due to cardiac toxicity induced by the effective concentrations of 2-20 g/ml. 34, 35 All-trans retinoic acid (ATRA) enhances IT activity by disrupting the Golgi apparatus and increasing the cytosolic routing of proteins. 36 The fungal metabolite brefeldin A influences the intracellular routing of internalized molecules and can enhance or block ricin A IT intoxication depending on the concentration used. [37] [38] [39] Thus it is unsuited for therapy.
In this study, we investigated the enhancement of the cytotoxicity of the anti-B cell IT CD22-rec ricin A using cell lines and B-CLL and B-ALL cells originating from patients. The aim was to select an agent that can be used in combination with the IT to purge bone marrow ex vivo, as well as treat patients suffering from B cell lymphoproliferative diseases. Serum has been described to inhibit the IT enhancing activity of monensin. 30, 40 Therefore the effect of the enhancers in combination with serum was assessed.
Materials and methods

Enhancers
Chloroquine (diphosphate salt), NH 4 Cl (cell culture), monensin, nigericin, leupeptin, perhexiline maleate, bacitracin, aprotinin, soybean trypsin inhibitor and brefeldin A were obtained from Sigma Chemical (St Louis, MO, USA). All-trans retinoic acid was generously provided by Hoffmann-La Roche (Basel, Switzerland). Verapamil was obtained from Knoll (Amsterdam, The Netherlands).
Cell lines
The B-lineage cell lines Daudi and Ramos (Burkitt lymphomas) were maintained in the log phase by culturing them in medium consisting of RPMI 1640 (Flow Labs, Irvine, UK) supplemented with 10% heat-inactivated fetal calf serum (Integro, Zaandam, The Netherlands), 2 mm glutamine, 50 U/ml penicillin and 50 g/ml streptomycin (Flow Labs) in a humidified incubator with 5% CO 2 in air at 37°C. Cells were maintained in log phase of cell growth.
Patient samples
Samples originated from one patient with T-acute lymphoblastic leukemia (ALL), two with B-ALL and three with B-chronic lymphocytic leukemia (B-CLL) ( Table 1 ). Mononuclear cells 
Monoclonal antibody
The murine MoAb CD22 (CLB-B-ly/1; IgGl) was purchased from the CLB (Amsterdam, The Netherlands). CD22 was produced in a hollow fiber bioreactor and was purified from the supernatant by affinity chromatography using staphylococcal protein A-Sepharose (Pharmacia).
CD22 binding assay
Ramos cells (10 5 ) were washed and incubated with various concentrations of CD22 (5 × 0 −12 to 1 × 10 −7 m) in 100 l 0, 50 or 100% human serum in PBS for 30 min at 4°C. After washing the cells were incubated with 5 l goat-anti-mouse IgG(H+L)F(abЈ) 2 -FITC (American Qualex, San Clemente, CA, USA) (prediluted 1:50) in 100 l 20% human serum for 30 min at 4°C. Samples were washed twice and analyzed by flow cytometry (Coulter Epics Elite; Coulter, Hialeah, FL, USA) for relative fluorescence intensity.
Immunotoxin preparation
CD22 was coupled to rec ricin A chain (generously provided by Zeneca Pharmaceuticals, Macclesfield, UK) by means of 4-succinimidyloxylcarbonyl-␣-methyl-␣-(2-pyridyldithio)-toluene (SMPT; synthesized by the Department of Organic Chemistry, University of Nijmegen, The Netherlands) using the method of Thorpe et al. 41 Briefly, 10 mg CD22 in 1 ml 25 mm sodium borate (pH 9) was treated with a 10-fold molar excess of SMPT (110 l of 1 mg/ml SMPT solved in N,N-dimethylformamide (DMF, Merck)) for 1 h at 20°C. Free SMPT and DMF were removed by G25 gel filtration. To introduce a free sulfhydryl group ricin A was incubated in 50 mm DTT for 30 min at 20°C. DTT was then removed by gel filtration on the G25 column. The modified MoAb was incubated with a 2.5 molar excess ricin A for 72 h at 20°C resulting in a coupling ratio (ricin A:MoAb) of 1.1. Free ricin A was separated from the IT by gel filtration on a Sephacryl S200 High Resolution (Pharmacia) column.
Protein synthesis inhibiting activity of CD22-rec ricin A
Cells (10 5 ) in culture medium were incubated with various concentrations ranging from 10 −13 to 10 −8 m CD22-rec ricin A in the presence or the absence of varying concentrations of potential enhancers in a final volume of 200 l. Before determining the potentiating activity of the enhancers, we incubated cells with a range of concentrations of each enhancer to define the maximum concentration in vitro, ie the concentration that did not inhibit protein synthesis for more than 30%. Protein synthesis inhibiting activity of CD22-rec ricin A was also assessed in the presence of pooled human serum collected from healthy donors. Cells were incubated in 96-well microtiter plates (Costar, Cambridge, MA, USA) in triplicate for 24 h at 37°C. Subsequently, 0.5 Ci (Amersham, Buckinghamshire, UK) was added. After a further 24 h, cells were harvested and incorporated radioactivity was determined. Cytotoxicity was expressed as the percentage 3 Hleucine incorporation inhibition of untreated cells corrected for non-specific incorporation determined by incubating cells in the presence of 1 mm cycloheximide (Boehringer, Mannheim, Germany).
Cell killing of cell lines by CD22-rec ricin A
Cell killing was determined according to a method previously described. 42 Briefly, cells were treated with 5 × 10 −11 m CD22-ricin A for 24 h in the absence or presence of varying concentrations of potential enhancers. The cells were then washed and incubated in culture medium for 3 days. Propidium iodide (PI; 2 g/ml) was added to stain dead cells and calcein (2 g/ml) to stain living cells 45 min before flow cytometric analysis (Coulter Epics Elite). Inert beads (5 × 10 4 /ml, DNACheck, Coulter) were added to enable the quantification of cell killing. The % of killed cells was calculated using the formula: ((number of viable cells in control sample per 1000 beads − number of viable cells in treated sample per 1000 beads)/number of viable cells in control sample per 1000 beads) × 100%.
Cell killing of B-CLL and B-ALL cells by CD22-rec ricin A
Patient cells (Table 1) 
Toxicity to bone marrow progenitor cells
Bone marrow was aspirated from healthy donors after informed consent was obtained. Erythrocytes and mature granulocytes were removed by gradient centrifugation on Ficoll (1.077 g/ml). Cells (10 6 /ml) were incubated with IT, monensin, nigericin, NH 4 Cl or chloroquine for 24 h and then washed. The decrease of progenitor cells was determined in clonogenic assays of granulocyte/macrophage colony-forming cells (CFU-GM) and erythroid burst-forming cells (BFU-E) as described previously. 43 
Results
Cytotoxic activity of CD22-rec ricin A to Daudi and Ramos cells
The cytotoxic activity of CD22-rec ricin A to the B cell lines Daudi and Ramos as determined in the protein synthesis inhibition assay is expressed by ID 50 values for Daudi and Ramos cells were 3.0 × 10 −11 m and 5.2 × 10 −11 m (data not shown). Enhancement of the activity of CD22-rec ricin A determined in the protein synthesis inhibition assay is expressed by the factor of enhancement (see Materials and methods).
In order to verify whether protein synthesis inhibition is equal to cell elimination and to quantify this elimination we investigated viability after treatment with 5 × 10 −11 m IT, approximately equivalent to the ID 50 value, in a recently developed quantitative cell killing assay. This IT concentration killed 41% of the Daudi and 42% of the Ramos cells ( Table  2 , Figure 1 ).
Influence of calcium-channel antagonists on CD22-rec ricin A cytotoxicity
The maximum concentration of verapamil (2 m) tolerated in vivo did not enhance CD22-recombinant ricin A. Verapamil concentrations of 5 mm and higher were too toxic for Daudi and Ramos and were not tested for enhancement. Perhexiline maleate (50-200 m) also did not enhance the activity of CD22-rec ricin A (data not shown).
Influence of brefeldin A and ATRA on CD22-rec ricin A activity
Brefeldin A was assessed to enhance CD22-rec ricin A in concentrations ranging from 1 ng/ml to 1 g/ml. Concentrations of up to 100 ng/ml did not enhance IT activity while concentrations of 100 ng/ml and higher as such reduced protein synthesis in Daudi and Ramos cells to less than 10%. Up to 50 m ATRA did not enhance CD22-rec ricin A activity (data not shown).
Effect of protease inhibitors on CD22-rec ricin A cytotoxicity
The protease inhibitors bacitracin, leupeptin, aprotinin and soybean trypsin inhibitor were investigated for CD22-rec ricin A cytotoxicity enhancing activity. The IT activity was enhanced two-fold by 500 m bacitracin (Table 3 ) whereas higher concentrations (1.0 mm) were toxic. Aprotinin (1-100 m), leupeptin (1-200 m) and soybean trypsin inhibitor (1-100 m) had no effect on CD22-rec ricin A activity.
Enhancement of CD22-rec ricin A cytotoxicity by carboxylic ionophores
The potency of monensin and nigericin to enhance CD22-rec ricin A activity was studied at concentrations of 5 and 10 nm. These concentrations were not toxic in the protein synthesis inhibition assay. Concentrations of monensin and nigericin of 25 nm appeared to be toxic in bone marrow progenitor clonogenic assays particularly to the erythroid progenitors (Table  4 ). In the quantitative cell killing assay 10 nm monensin and nigericin reduced the viability by up to 7% of Daudi and Ramos cells (data not shown). Nigericin potentiated the IT cytotoxicity more effectively than monensin (Table 3) . At 10 nm, monensin enhanced the IT activity as determined by a reduction of the ID 50 in the protein synthesis inhibition assay, 117-and 81-fold in Daudi and Ramos cells, respectively. Ten n m nigericin enhanced the IT activity 382-fold in Daudi cells and 318-fold in Ramos cells, respectively.
We also studied enhancement of elimination of target cells (Figure 1 ). In agreement with the results of the protein synthesis inhibition assay we observed in the quantitative cell killing assay that nigericin potentiated stronger the cytotoxicity of CD22-rec ricin A towards Daudi and Ramos cells than monensin (Table 2) . At 5 × 10 −1 m, CD22-rec ricin A killed 41% of the Daudi cells and 42% of the Ramos cells ( Figure  1 ). In the presence of 10 nm monensin, the IT killed 74% of the Daudi cells and 99% of the Ramos cells and when exposed to the same concentration of nigericin, the IT killed 96% of the Daudi cells and 99% of the Ramos cells (Table 2) .
Human serum blocks the enhancing activity of monensin. 30, 40 We confirmed that enhancement by both monensin (Figure 2 ) and nigericin (data not shown) was completely blocked when the assay was performed in 50% human serum. We found that the activity of CD22-rec ricin A was also impaired by human serum. The ID 50 of CD22-rec ricin A for Ramos was reduced 11-fold in the presence of 50% human The factor of enhancement is defined as the ID 50 of CD22-rec ricin A divided by the ID 50 of CD22-rec ricin A in the presence of an enhancer. ID 50 s were determined in protein synthesis inhibition assays which were performed in triplicate. Assays were repeated twice. The toxicity of varying concentrations of enhancers to bone marrow progenitor cells was determined as described in Materials and methods. Assays were performed three times. s.d. Ͻ 10%.
serum and 58-fold in the presence of 100% human serum ( Figure 3 ). Reduction in IT activity was not caused by reduced binding of CD22 as this was not affected by 50% and 100% human serum (Figure 4) .
Influence of lysosomotropic amines on CD22-rec ricin A activity
The lysosomotropic amines NH 4 Cl and chloroquine were investigated for CD22-rec ricin A activity enhancing potency. At 6 mm, NH 4 Cl inhibited 18% of protein synthesis. Fifty m chloroquine reduced the protein synthesis of Daudi and Ramos to 93 and 70%, respectively. A concentration of 100 m reduced the protein synthesis to less than 25% (data not shown), and was therefore not studied for enhancement of CD22-rec ricin A. Previously we showed that 6 mm NH 4 Cl enhanced the CD22-rec ricin A activity to eight different B cell lines between seven-and 93-fold. 6 Chloroquine enhanced the activity of CD22-rec ricin A in a dose-dependent fashion (Table 3) with 50 m chloroquine enhancing the IT activity 14-fold for Daudi cells and 11-fold for Ramos cells.
Human serum reduced, but did not completely block the enhancement of CD22-rec ricin A by chloroquine (Figure 3) . At 50 m, chloroquine enhanced the IT cytotoxicity 2.6-and 1.7-fold in the presence of 50% or 100% human serum, respectively.
The combination of 6 mm NH 4 Cl and either 5 or 20 m
Figure 3
Influence of human serum on the cytotoxicity of CD22-rec ricin A and on enhancement by chloroquine in the cell line Ramos. Cytotoxicity was determined in a protein synthesis inhibition assay in the presence of 0% (ć), 50% () or 100% (̅) human serum and in the presence of 50 mm chloroquine and 0% (b), 50% () or 100% (̆) human serum. Assays were performed in triplicate and repeated twice. s.d. Ͻ 10%.
Figure 4
Influence of 50% () and 100% (̅) human serum on binding of the CD22 MoAb (ć) to Ramos cells performed as described in Materials and methods.
chloroquine enhanced the activity CD22-rec ricin A against Daudi and Ramos cells by more than the sum of the enhancement by both agents individually (145-and 107-fold, respectively, Table 3, Figure 5 ). These combinations reduced the protein synthesis of Daudi and Ramos cells by only 18% (data not shown) and were not toxic in bone marrow progenitor assays (Table 4) .
Activity of CD22-rec ricin A to B-CLL and B-ALL cells
The activity of CD22-rec ricin A in combination with enhancers against malignant cells originated from three patients with B-CLL and two patients with B-ALL was determined by the flow cytometric cell killing assay (Table 5 ). B-CLL cells (mean killing 0.42 log) seemed more sensitive to the IT than B-ALL cells (mean killing 0.19 log). Normal B cells were also killed by the IT (Table 5 ). Malignant T cells and normal T cells were not affected (data not shown). The enhancers that potentiated IT activity to the cell lines Daudi and Ramos were assessed for IT enhancing activity to these malignant cells. The enhancers were hardly toxic for the cells (Table 5) . NH 4 Cl (mean log kill 1.70 and 1.52), chloroquine (mean log kill 1.51 and 0.47), monensin (mean log kill 1.44 and 0.59) and nigericin (mean log kill 1.43 and 0.96) all enhanced the activity of the IT against the B-CLL and B-ALL cells, respectively. However, the combination of chloroquine and NH 4 Cl potentiated the IT activity against B-CLL and B-ALL cells to the greatest extent with a mean log kill of 2.06 and 1.85, respectively.
Discussion
ITs are a promising treatment modality for malignancies either as initial therapy or as adjuvant therapy. Efficacy of IT treatment may be improved by several approaches such as applying varying MoAbs and toxins 44 or IT cytotoxicity enhancing agents. 19, 27, 28, 33, 37 We studied the enhancing effect of various agents on the activity of CD22-rec ricin A on the cell lines Daudi and Ramos and B-CLL, B-ALL and normal B cells using protein synthesis inhibition assays and quantitative flow cytometric cell killing assays.
In protein synthesis inhibition assays, 3 H-leucine incorporation is measured. The correlation of protein synthesis inhibition with cell elimination remains questionable. Therefore an assay should be used in which cell kill is determined. Clonogenic assays of limiting dilutions should be suitable but are laborious, time-consuming and only applicable for in vitro proliferating cells. We therefore employed an assay we recently developed in which cell elimination was determined by flow cytometry by combining cell killing parameters and immunofluorescence. The depletion of CD22 + B cells was determined by the quantitative cell killing assay. The activity of CD22-rec ricin A to B-CLL (1, 2, 3) , B-ALL (4, 5) and normal B cells derived from a T-ALL patient (6) was investigated. Depletion (log kill) is determined by log (number of viable cells in treated sample per 1000 beads/number of viable cells in control sample per 1000 beads). ND, not determined.
CD22-rec ricin A was highly cytotoxic to Daudi and Ramos cells with ID 50 of approximately 5 × 10 −11 m as determined by the protein synthesis inhibition assay. In flow cytometric cell killing assays we determined that this concentration killed approximately 40% of these target cells. There was little agreement on enhancement between the two assays (Tables  2 and 3 ). Although 10 nm monensin and nigericin enhanced IT activity in the protein synthesis inhibition assay against Daudi cells to a greater extent than against Ramos cells, the former cells were killed less effectively after exposure to monensin and nigericin. More Daudi cells were killed by 5 × 10 −11 m IT in the presence of 5 nm nigericin than in the presence of 10 nm monensin, although 10 nm monensin enhanced to a greater extent than did 5 nm nigericin when measured by the protein synthesis inhibition assay (Tables 1  and 2 ). Protein synthesis does not completely reflect the cytotoxic activity of ITs possibly because of the relatively long time it takes ITs to exert their action which may allow a cell to recover from incomplete or insufficient protein synthesis inhibition. Thus it is preferable to determine the effectiveness of ITs using an assay that measures cytotoxicity directly, as used in this study.
Though ATRA, verapamil and brefeldin A have been shown to enhance the activity of ricin A ITs, 34,36,37 these agents did not enhance CD22-rec ricin A activity. These varying results might be explained if ricin A follows a different intracellular routing after it is delivered to the cells by CD22 MoAb than occurs with other cell binding moieties. Alternatively, different target cells might exhibit different susceptibility to the different enhancers. Similar contradictory results have been obtained with NH 4 Cl. 6 Monensin, nigericin, NH 4 Cl, chloroquine and bacitracin all enhanced the activity of CD22-rec ricin A. Nigericin was more potent than the combination of chloroquine and NH 4 Cl, which in turn was more potent than monensin and bacitracin. The combination of chloroquine and NH 4 Cl was more potent than both agents individually.
In order to apply ITs in combination with enhancing agents in vivo we studied the enhancement in the presence of human serum. We confirmed the results of Candiani et al 30 and Franceschi et al 40 who showed that monensin is unsuitable for use in vivo because it forms complexes with serum components thereby losing its ability to enhance IT. Human serum also abrogated the enhancing activity of nigericin. Furthermore we showed that human serum inhibited the activity of CD22-rec ricin A itself in a concentration-dependent fashion. We could not detect any degradation of the IT after incubation in 50% human serum for 24 h at 37°C (by means of immunoblotting; data not shown) yet only 10% of the activity was retained. This reduced activity can not be caused by instability of the disulphide bond between the MoAb and toxin of the IT in serum nor by reduced binding of the CD22 antibody as this was unaffected by human serum (Figure 3) . We assume that CD22-rec ricin A is inhibited by complexation of the IT with serum components as described for monensin. 30, 40 Inhibition of activity might also be induced by covalent binding of ␣ 2 -macroglobulin to rec ricin A as has been described for deglycosylated ricin A chain and its ITs by Ghetie et al 45 who found a substantial amount of complexes formed after 24 h. However, we could not detect these high molecular complexes with the immunoblotting assay used. Besides, the kinetics of CD22-rec ricin A activity are too fast 6 to allow these complexes to form. 45 This suggests that more factors contribute to the reduction of IT activity by serum. We assume that CD22-rec ricin A activity is inhibited as a result of complexes formed with human serum components and that these impede internalization of this IT.
The activity of chloroquine was partially blocked in the presence of human serum so we intend to pursue this further in mice models to assess its potential for improving the activity of CD22-rec ricin A in vivo.
Cytotoxicity of CD22-rec ricin A against malignant B-CLL and B-ALL cells was studied in the flow cytometric cell killing assay. B-CLL cells seem to be eliminated more effectively by the IT than do B-ALL and normal B cells. IT activity to malignant B cells was enhanced by NH 4 Cl, chloroquine, monensin and nigericin but the combination of NH 4 Cl and chloroquine was more effective in contrast to enhancement of IT activity against cell lines. CD22-rec ricin A was more active in killing B cell lines than cells originating from patients which may be the result of the cell lines ability to proliferate in vitro.
We conclude that monensin, nigericin or the combination of chloroquine and NH 4 Cl are very effective enhancers of CD22-rec ricin A and can be used to treat bone marrow contaminated with malignant B cells ex vivo.
